Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=award_amount
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_amount", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=award_amount", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=award_amount", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=award_amount" }, "data": [ { "type": "Grant", "id": "9211", "attributes": { "award_id": "75N91019D00024-0-759102000025-1", "title": "DCR IS REQUESTING THE SERVICES OF LEIDOS BIOMEDICAL RESEARCH, INC. TO INITIATE MANAGEMENT, OVERSIGHT, EXECUTION, CLOSEOUT AND PUBLICATION OF FINDINGS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-28", "end_date": "2025-09-27", "award_amount": 2539503, "principal_investigator": { "id": 23964, "first_name": "ETHAN", "last_name": "DMITROVSKY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The base of this funding will support an overall framework to allow NIAID to exercise up to 13 options for studies dealing with emerging and re-emerging Infectious Diseases that may include COVID-19.", "keywords": [ "Adult", "Biomedical Research", "COVID-19", "Characteristics", "Child", "Clinical", "Emerging Communicable Diseases", "Etiology", "Exercise", "Fever", "Funding", "National Institute of Allergy and Infectious Disease", "Observational Study", "Outcome", "Publications", "Services", "base", "pediatric patients", "prospective" ], "approved": true } }, { "type": "Grant", "id": "15763", "attributes": { "award_id": "1RF1NS138437-01A1", "title": "Impact of SARS-CoV-2 on the cerebrovasculature as a risk factor for VCID: Role of Wnt/beta-catenin", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 32579, "first_name": "WILLIAM PATRICK", "last_name": "DALEY", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-11", "end_date": "2029-07-31", "award_amount": 2549080, "principal_investigator": { "id": 31999, "first_name": "Sarah Elizabeth", "last_name": "Lutz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2631, "ror": "", "name": "UNIVERSITY OF ILLINOIS AT CHICAGO", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "COVID-19 increases the risk of vascular contributions to cognitive impairment and dementia (VCID). VCID is one of the most prevalent forms of dementia, so the potential public health impact of the COVID-19 pandemic on future VCID is substantial. However, the mechanisms by which COVID-19 modifies VCID are unknown. Identifying mechanisms that regulate how prior COVID-19 influences the brain endothelial cell response to vascular stress is important. Here, we provide preliminary evidence that COVID-19 decreases resistance to VCID by weakening the blood-brain barrier (BBB). This is accompanied by cerebrovascular inflammation. This grant will test the novel mechanism that SARS-CoV-2 infection accelerates VCID by suppressing cerebrovascular Wnt/β-catenin signaling. In Aim 1, we determine how prior SARS-CoV-2 infection influences BBB permeability and cognition upon subsequent vascular insult, by genetic and epigenetic modification. In Aim 2 we use endothelial-targeted genetic interventions to assess the contribution of Wnt/β- cat targets to resistance to post-infectious VCID. In Aim 3, we ask whether established post-infectious VCID can be reversed by increasing cerebrovascular Wnt/β-catenin. These studies could lead to novel approaches to identify individuals at high risk for VCID and novel potential therapeutic strategies to mitigate the impact of prior infection on the development of dementia.", "keywords": [ "2019-nCoV", "ATAC-seq", "Acceleration", "Acute", "Blood - brain barrier anatomy", "Blood Vessels", "Blood brain barrier dysfunction", "COVID-19", "COVID-19 pandemic effects", "Cells", "Cerebrovascular system", "Clinic", "Cognition", "Critical Pathways", "Data", "Dementia", "Development", "Endothelial Cells", "Endothelium", "Engineering", "Epigenetic Process", "Extravasation", "Functional disorder", "Future", "Genes", "Genetic", "Goals", "Grant", "High Fat Diet", "Human", "Hypertension", "Impaired cognition", "Individual", "Infection", "Inflammation", "Inflammatory", "Knowledge", "Ligands", "Modification", "Mus", "Pathogenicity", "Pathway interactions", "Pattern", "Pericytes", "Permeability", "Phenotype", "Prevention", "Public Health", "Recording of previous events", "Recovery", "Research", "Resistance", "Respiratory Tract Infections", "Risk", "Risk Factors", "Role", "SARS-CoV-2 infection", "Signal Transduction", "Testing", "Therapeutic", "Translating", "Vascular Dementia", "Viral", "beta catenin", "blood-brain barrier permeabilization", "brain endothelial cell", "cerebrovascular", "gene therapy", "high risk", "in vivo", "inhibitor", "macromolecule", "mouse model", "neuroinflammation", "neurotoxic", "novel", "novel strategies", "post SARS-CoV-2 infection", "post-pandemic", "prevent", "programs", "promote resilience", "respiratory", "response", "small molecule", "therapeutic target", "transcriptome sequencing", "vascular cognitive impairment and dementia", "vascular stress" ], "approved": true } }, { "type": "Grant", "id": "4561", "attributes": { "award_id": "1532169", "title": "MRI: Development of VIRUS2 - A Scalable Integral Field Spectrograph for McDonald Observatory", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Mathematical and Physical Sciences (MPS)", "Major Research Instrumentation" ], "program_reference_codes": [], "program_officials": [ { "id": 15726, "first_name": "Zoran", "last_name": "Ninkov", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2015-10-31", "end_date": "2021-09-30", "award_amount": 2549713, "principal_investigator": { "id": 15729, "first_name": "Gary", "last_name": "Hill", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 156, "ror": "", "name": "University of Texas at Austin", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 15727, "first_name": "Niv", "last_name": "Drory", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 15728, "first_name": "Hanshin", "last_name": "Lee", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 156, "ror": "", "name": "University of Texas at Austin", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "This award funds the development of a new astronomical instrument at the McDonald Observatory in West Texas. The VIRUS2 spectrograph design will be well-adapted to future applications on the next generation of extremely large telescopes, and offers a cost-effective way to instrument such telescopes. This program will provide the opportunity for students to be involved in the design, assembly, and commissioning of the instrument. \n\nVIRUS2 is a scalable Integral Field Spectrograph for the McDonald Observatory 2.7-m telescope. It will be based on technology developed for the original VIRUS instrument on the Hobby Eberly Telescope (HET), also at McDonald. The VIRUS spectrograph is adaptable to a range of spectral resolutions and wavelengths. VIRUS2 will utilize three replicated units to cover wavelengths 370-915 nm at resolution ~2300. The large investment already made in VIRUS makes this follow-on project lower in cost than starting from scratch and should allow for a rapid schedule and low risk. The resulting instrument will enable studies complementary to ongoing structure surveys of nearby galaxies (MaNGA, SAMI, CALIFA, VENGA) by extending observations to the outskirts of galaxies.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6639", "attributes": { "award_id": "5U19AI135995-05", "title": "Consortium for Viral Systems Biology (CViSB)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22268, "first_name": "REED SOLOMON", "last_name": "Shabman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2018-02-01", "end_date": "2023-01-31", "award_amount": 2550000, "principal_investigator": { "id": 22269, "first_name": "Kristian Graugaard", "last_name": "Andersen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 745, "ror": "", "name": "SCRIPPS RESEARCH INSTITUTE, THE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Modified Project Summary/Abstract Section The Ebola epidemic that ravaged West Africa from 2013 to 2016 is by far the largest outbreak ever recorded. Weak healthcare infrastructure, community resistance, and a slow uncoordinated response allowed the epidemic to spin out of control. The region, however, is no stranger to dealing with viral hemorrhagic fevers. Lassa fever is caused by infection with Lassa virus and is hyper-endemic in West Africa. Lassa fever is similar to Ebola in that infection with Lassa virus can lead to a severe hemorrhagic fever. Infections with both Lassa virus and Ebola virus can lead to deaths in more than 70% of hospitalized patients. It is estimated that tens of thousands of people die from Lassa fever each year. These numbers are likely underestimates, as the healthcare infrastructure in the affected countries is extremely weak, surveillance almost non-existent, and most patients never present in the hospital. Despite the high case fatality rates of hospitalized Ebola and Lassa fever patients, however, some people appear to be able to quickly fight the viruses, whereas others die quickly from infection. Yet, what distinguishes fatal from non-fatal disease and the development of symptomatic versus asymptomatic infection, remain largely unknown and severely understudied. The recent COVID-19 global pandemic has presented identical challenges and research questions as Ebola and Lassa Fever. The goal of the Consortium for Viral Systems Biology is to uncover the virus and human factors that determine how infected individuals are able to better fight the viruses. We will achieve this goal by investigating the following three broad aims: Aim 1. Define virus and host factors responsible for survival and non-survival in Ebola, Lassa fever and COVID-19 patients. Aim 2. Identify factors that play roles in the development of severe long-term symptoms in survivors. Aim 3. Define factors that determine whether human individuals develop symptomatic or asymptomatic disease. We will accomplish these aims by applying several ‘omics’ technologies, physiological measurements, and high-throughput experimental approaches to unique patient and survivor cohorts of COVID-19, Lassa fever and Ebola. We will develop novel predictive statistical models for identifying critical disease correlates and analyze large-scale data sets to pinpoint causal host-pathogen interactions. By elucidation the molecular networks that play critical roles in patient outcomes, this research will allow us to identify new targets for medicines and vaccines and inform personalized treatment strategies. Our study will also provide novel research frameworks and computational algorithms applicable to a wide range of other human pathogens.", "keywords": [ "2019-nCoV", "Address", "Affect", "Africa", "Binding", "Biological", "COVID-19", "COVID-19 pandemic", "COVID-19 patient", "COVID-19 survivors", "Case Fatality Rates", "Cessation of life", "Clinical", "Communities", "Computational algorithm", "Country", "Data Set", "Development", "Disease", "Disease Marker", "Disease Outbreaks", "Ebola", "Ebola Hemorrhagic Fever", "Ebola virus", "Epidemic", "Future", "Genetic", "Goals", "Healthcare", "Hospitals", "Human", "Immunologics", "Immunotherapeutic agent", "Individual", "Infection", "Infrastructure", "Integration Host Factors", "Investigation", "Lassa Fever", "Lassa virus", "Lead", "Measurement", "Medicine", "Mission", "Molecular", "Outcome", "Outcomes Research", "Patient-Focused Outcomes", "Patients", "Persons", "Physiological", "Play", "Research", "Research Infrastructure", "Resistance", "Role", "Severities", "Statistical Models", "Survivors", "Symptoms", "System", "Systems Biology", "Technology", "Vaccines", "Viral", "Viral Hemorrhagic Fevers", "Virus", "Work", "cohort", "coronavirus disease", "data access", "data tools", "fighting", "human disease", "human pathogen", "innovation", "insight", "large scale data", "member", "microbial", "neutralizing antibody", "novel", "pathogen", "personalized medicine", "predictive marker", "predictive modeling", "programs", "public health relevance", "response", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "7654", "attributes": { "award_id": "5U19AI135995-03", "title": "Consortium for Viral Systems Biology (CViSB)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6044, "first_name": "REED SOLOMON", "last_name": "Shabman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2018-02-01", "end_date": "2023-01-31", "award_amount": 2550000, "principal_investigator": { "id": 6045, "first_name": "Kristian Graugaard", "last_name": "Andersen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 745, "ror": "", "name": "SCRIPPS RESEARCH INSTITUTE, THE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 745, "ror": "", "name": "SCRIPPS RESEARCH INSTITUTE, THE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Modified Project Summary/Abstract Section The Ebola epidemic that ravaged West Africa from 2013 to 2016 is by far the largest outbreak ever recorded. Weak healthcare infrastructure, community resistance, and a slow uncoordinated response allowed the epidemic to spin out of control. The region, however, is no stranger to dealing with viral hemorrhagic fevers. Lassa fever is caused by infection with Lassa virus and is hyper-endemic in West Africa. Lassa fever is similar to Ebola in that infection with Lassa virus can lead to a severe hemorrhagic fever. Infections with both Lassa virus and Ebola virus can lead to deaths in more than 70% of hospitalized patients. It is estimated that tens of thousands of people die from Lassa fever each year. These numbers are likely underestimates, as the healthcare infrastructure in the affected countries is extremely weak, surveillance almost non-existent, and most patients never present in the hospital. Despite the high case fatality rates of hospitalized Ebola and Lassa fever patients, however, some people appear to be able to quickly fight the viruses, whereas others die quickly from infection. Yet, what distinguishes fatal from non-fatal disease and the development of symptomatic versus asymptomatic infection, remain largely unknown and severely understudied. The recent COVID-19 global pandemic has presented identical challenges and research questions as Ebola and Lassa Fever. The goal of the Consortium for Viral Systems Biology is to uncover the virus and human factors that determine how infected individuals are able to better fight the viruses. We will achieve this goal by investigating the following three broad aims: Aim 1. Define virus and host factors responsible for survival and non-survival in Ebola, Lassa fever and COVID-19 patients. Aim 2. Identify factors that play roles in the development of severe long-term symptoms in survivors. Aim 3. Define factors that determine whether human individuals develop symptomatic or asymptomatic disease. We will accomplish these aims by applying several ‘omics’ technologies, physiological measurements, and high-throughput experimental approaches to unique patient and survivor cohorts of COVID-19, Lassa fever and Ebola. We will develop novel predictive statistical models for identifying critical disease correlates and analyze large-scale data sets to pinpoint causal host-pathogen interactions. By elucidation the molecular networks that play critical roles in patient outcomes, this research will allow us to identify new targets for medicines and vaccines and inform personalized treatment strategies. Our study will also provide novel research frameworks and computational algorithms applicable to a wide range of other human pathogens.", "keywords": [ "Address", "Affect", "Africa", "Binding", "Biological", "Case Fatality Rates", "Cessation of life", "Clinical", "Communities", "Computational algorithm", "Country", "Data Set", "Development", "Disease", "Disease Marker", "Disease Outbreaks", "Ebola", "Ebola Hemorrhagic Fever", "Ebola virus", "Epidemic", "Future", "Genetic", "Goals", "Healthcare", "Hospitals", "Human", "Immunologics", "Immunotherapeutic agent", "Individual", "Infection", "Infrastructure", "Integration Host Factors", "Investigation", "Lassa Fever", "Lassa virus", "Lead", "Measurement", "Medicine", "Mission", "Molecular", "Outcome", "Outcomes Research", "Patient-Focused Outcomes", "Patients", "Physiological", "Play", "Research", "Research Infrastructure", "Resistance", "Role", "Severities", "Statistical Models", "Survivors", "Symptoms", "System", "Systems Biology", "Technology", "Vaccines", "Viral", "Viral Hemorrhagic Fevers", "Virus", "Work", "cohort", "data access", "data tools", "fighting", "human disease", "human pathogen", "innovation", "insight", "large scale data", "member", "microbial", "neutralizing antibody", "novel", "pathogen", "personalized medicine", "predictive marker", "predictive modeling", "programs", "response", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "14050", "attributes": { "award_id": "75N95023D00001-0-759502300004-1", "title": "N3C CIO SUPPORT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-02-14", "end_date": "2023-10-31", "award_amount": 2550000, "principal_investigator": { "id": 26488, "first_name": "GARY", "last_name": "MAYS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, https://covid.cd2h.org/, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C program is essentially a medium sized business, consisting of thousands of researchers, requiring enterprise level information technology (IT) support as part of a virtual research organization (VRO). This contract is necessary to ensure that NCATS and N3C can continue to provide adequate support for a secure, collaborative, VRO. This contract allows for continued support of the VRO which supports all of the required information technology functions to support an environment of over 4,000 users, including cloud-based productivity tools, a service desk, commercial and open-source deployments of analytical tools for the community to use, and expansion of the data types available for analysis, such as imaging, viral variant genomic sequences, etc. The common need is to share a collaborative cloud environment capable of ingesting billions of data points and performing a variety of complex analyses against multimodal data types, ranging from pathology and radiology data, synthetic data, genomic information, electronic health records (EHRs) and a wide variety of others. All of this must be done while meeting the highest levels of security and privacy, given the sensitivity of some of the data types being collected and the importance of the work being done in the environment. This contract provides support for all of these enterprise IT efforts.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10541", "attributes": { "award_id": "1RF1MH132336-01", "title": "Cellular models of fetal neurodevelopment in maternal SARS-CoV-2 infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 6363, "first_name": "Julia L", "last_name": "Zehr", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-15", "end_date": "2025-09-14", "award_amount": 2560905, "principal_investigator": { "id": 21683, "first_name": "Andrea Goldberg", "last_name": "Edlow", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 26553, "first_name": "ROY H.", "last_name": "Perlis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The impact of maternal SARS-CoV-2 infection on the developing fetus remains unknown, but preliminary data has begun to accumulate suggesting neurodevelopmental effects in offspring. There is compelling evidence that the fetal brain is particularly vulnerable to maternal immune activation and inflammatory exposures during key developmental windows. In light of the projection that millions of fetuses will ultimately be exposed to COVID- 19, understanding and modeling this risk is a pressing scientific and public health concern. While long-term clinical outcomes cannot be known for a decade or more, tools to model risk for adverse neurodevelopmental outcomes, understand mechanisms of risk, and to screen for interventions, are urgently needed. Microglia, the resident brain immune cells, play a critical role in normal brain development, and are known to be impacted by the intrauterine environment. The investigators have developed and validated methods to efficiently generate human microglia-like cells from peripheral blood, including umbilical cord blood. They demonstrated previously that these cells recapitulate morphology, transcriptome, and function of microglia derived from postmortem brain. Further, these models identify schizophrenia-associated pruning dysfunction, using a scalable synaptosome model as well as long-term co-culture. Here, the investigators propose to characterize effects of maternal SARS-CoV-2 infection using the large biospecimen bank they have created that includes matched maternal blood and neonatal cord blood, linked to abundant clinical detail and electronic health records. The bank includes more than 800 neonates of mothers who are SARS-CoV-2 positive (547), or SARS-CoV-2 negative and pregnant during the pandemic (265). Specifically, the investigators will characterize maternal immune activation via multiple cellular and serum measures. They will then create personalized neonatal models of microglial function using banked umbilical cord blood mononuclear cells. They will compare morphologic, transcriptomic, and functional differences between induced microglial cells from SARS-CoV-2-exposed and unexposed neonates, to test the hypothesis that SARS- CoV-2-related maternal immune activation primes microglial cells in utero toward an inflammatory phenotype, leading to dysregulated neurodevelopment. Finally, they will create an electronic health records cohort of more than 10,000 deliveries to examine risk for neurodevelopmental diagnoses among offspring of SARS-CoV-2 positive compared to negative mothers, ultimately capturing up to 5 years of follow-up. Together, these experiments will quantify the potential impact of maternal viral infection and immune activation on the developing fetal brain, examine a potential biomarker of risk, and develop a model system that may be used to identify and test interventions to minimize such risk. The project integrates laboratories with expertise in the impact of environmental exposures on maternal immune activation and developmental outcomes, patient-derived in vitro cellular modeling, and analysis of longitudinal electronic health records.", "keywords": [ "2019-nCoV", "Adult", "Affect", "Age", "Antibodies", "Apoptotic", "Autopsy", "Biological Assay", "Biological Models", "Biological Specimen Banks", "Birth", "Blood", "Blood Cells", "Brain", "COVID-19", "COVID-19 impact", "Cell model", "Cells", "Cellular Assay", "Child", "Clinical", "Coculture Techniques", "Data", "Development", "Diagnosis", "Dose", "Electronic Health Record", "Environmental Exposure", "Environmental Impact", "Exposure to", "Fetal Development", "Fetus", "Functional disorder", "Human", "Immune", "Immune system", "Immunity", "Immunological Models", "In Vitro", "Individual", "Infection", "Inflammation", "Inflammatory", "Influenza", "Intervention", "Investigation", "Laboratories", "Life", "Light", "Link", "Measures", "Mediating", "Methods", "Microglia", "Modeling", "Mononuclear", "Morphology", "Mothers", "Neonatal", "Neurodevelopmental Disorder", "Newborn Infant", "Outcome", "Parents", "Patients", "Peripheral Blood Mononuclear Cell", "Phagocytes", "Phagocytosis", "Phenotype", "Play", "Pregnancy", "Pregnant Women", "Prevention", "Property", "Protocols documentation", "Proxy", "Public Health", "Regulation", "Research Personnel", "Risk", "Role", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "SARS-CoV-2 negative", "SARS-CoV-2 positive", "Schizophrenia", "Serum", "Surface", "Synapses", "Synaptic plasticity", "Synaptosomes", "T-Lymphocyte", "Testing", "Therapeutic", "Tissues", "Training", "Umbilical Cord Blood", "Virus", "Virus Diseases", "Woman", "Yolk Sac", "acute infection", "biobank", "cohort", "complement system", "cytokine", "experimental study", "fetal", "follow-up", "immune activation", "in utero", "induced pluripotent stem cell", "intrauterine environment", "longitudinal analysis", "macrophage", "monocyte", "neonate", "neurodevelopment", "neurodevelopmental effect", "neurogenesis", "neuropsychiatric symptom", "offspring", "pandemic disease", "potential biomarker", "pregnant", "progenitor", "relating to nervous system", "response", "small molecule", "stem cells", "synaptic pruning", "tool", "transcriptome", "transcriptomics", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "12084", "attributes": { "award_id": "1RF1AG084178-01", "title": "Post-Acute Sequelae of SARS-CoV-2 Infection and Subsequent Disease Progression in Individuals with AD/ADRD: Influence of the Social and Environmental Determinants of Health", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8882, "first_name": "PARTHA", "last_name": "BHATTACHARYYA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2026-08-31", "award_amount": 2561480, "principal_investigator": { "id": 10734, "first_name": "Jiang", "last_name": "Bian", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 891, "ror": "https://ror.org/04b6nzv94", "name": "Brigham and Women's Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 4802, "first_name": "Fei", "last_name": "Wang", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 686, "ror": "", "name": "Joan and Sanford I. Weill Medical College of Cornell University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, { "id": 10736, "first_name": "Hui", "last_name": "Hu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 891, "ror": "https://ror.org/04b6nzv94", "name": "Brigham and Women's Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The global pandemic of the 2019 novel coronavirus disease (COVID-19) has severe consequences. Recent studies showed that individuals with COVID-19 had increased risk of an array of postacute incident neurologic sequelae, including cognition and memory disorders, in 12 months after COVID-19 diagnosis. Despite elevated risks of postacute neurologic outcomes of COVID-19 observed in the general population, little is known about Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) in cognitively impaired individuals (e.g., those with mild cognitive impairment [MCI] and Alzheimer’s disease [AD]/AD-related dementias [ADRD]) and how it may impact their subsequent disease progression. The rapid adoption of electronic health record (EHR) systems has made longitudinal clinical data available for research, especially for individuals with MCI or AD/ADRD who engage in frequent routine care. However, existing large EHR-based COVID-19 cohorts do not specifically focus on cognitively impaired individuals have several key limitations, including (1) missing or inaccurate information on cognitive impairment, (2) challenges to characterize disease progression in individuals with MCI or AD/ADRD, and (3) robust causal modeling approaches that can account for the complex confounding and selection biases in observational RWD. More importantly, little is known about factors contributing to PASC and subsequent disease progression in cognitively impaired individuals with COVID-19. It has long been recognized that social and environmental determinants of health (SEDH) play important roles in cognitive health. Exposures to multiple SEDH have been associated with MCI and AD/ADRD. Our recent studies (R21ES032762 and the RECOVER Initiative) also found that SEDH are associated with COVID-19 incidence, severity, mortality, and PASC in the general population. Individuals are exposed to multiple SEDH simultaneously, and the exposome is an ideal framework to rigorously examine how SEDH impacts cognitively impaired individuals’ susceptibility to PASC and subsequent disease progression. Building upon our prior and ongoing work on COVID-19 and PASC in the general population with the RECOVER Initiative, sub-phenotyping and disease progression modeling, and multiple SEDH, we will (1) understand the epidemiology of PASC in individuals with MCI or AD/ADRD with high-throughput causal inference approaches, (2) examine the impacts of COVID-19 and PASC on subsequent disease progression in individuals with MCI or AD/ADRD with a novel dynamic topic modeling approach, and (3) assess how SEDH contribute to PASC and subsequent disease progression in individuals with MCI or AD/ADRD with the exposome conceptual framework. This project will fill important knowledge gaps on our understanding of, especially SEDH’s contributions to, risks of PASC and subsequent disease progression in individuals with cognitive impairment.", "keywords": [ "2019-nCoV", "Acute", "Adoption", "Advanced Development", "Air Pollution", "Alabama", "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease related dementia", "Antigens", "COVID-19", "COVID-19 diagnosis", "COVID-19 impact", "Clinical", "Clinical Data", "Cognition Disorders", "Cognitive", "Complex", "Connecticut", "Data", "Data Sources", "Dementia", "Disease Progression", "Electronic Health Record", "Environment", "Epidemiology", "Exposure to", "Florida", "Future", "General Population", "Health", "Heterogeneity", "Impaired cognition", "Incidence", "Individual", "Knowledge", "Laboratories", "Link", "Massachusetts", "Measures", "Medical History", "Medicine", "Memory Disorders", "Methods", "Modeling", "Nature", "Neighborhoods", "Neurologic", "Neurological outcome", "New Hampshire", "New Jersey", "New York", "Pathway interactions", "Patients", "Pattern", "Phenotype", "Play", "Polymerase Chain Reaction", "Positioning Attribute", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Pragmatic clinical trial", "Predisposition", "Prevention strategy", "Publishing", "Research", "Risk", "Risk Factors", "Role", "SARS-CoV-2 positive", "Selection Bias", "Severities", "Social Environment", "Syndrome", "Testing", "Vital Statistics", "Work", "body system", "causal model", "cohort", "coronavirus disease", "data registry", "deep learning", "deprivation", "electronic health record system", "health determinants", "mild cognitive impairment", "mortality", "neurologic sequelae of COVID-19", "novel", "pandemic disease", "repository", "routine care", "social", "social influence", "success", "treatment strategy", "walkability" ], "approved": true } }, { "type": "Grant", "id": "8814", "attributes": { "award_id": "1P01AI165072-01", "title": "Features of Broad T Cell Coronavirus Immunity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-16", "end_date": "2024-08-31", "award_amount": 2572892, "principal_investigator": { "id": 24615, "first_name": "ANDREW D", "last_name": "LUSTER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 891, "ror": "https://ror.org/04b6nzv94", "name": "Brigham and Women's Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 891, "ror": "https://ror.org/04b6nzv94", "name": "Brigham and Women's Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project 2 Summary Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 coronavirus, has quickly become a global health crisis of epic proportion. This pandemic, along with the SARS-CoV epidemic of 2002 and MERS-CoV epidemic of 2012, highlights the tremendously dangerous ongoing threat to humanity posed by emerging human-tropic coronaviruses that are transitioning from bats and other wildlife species into humans. Thus, while early vaccines for SARS-CoV-2 have already demonstrated remarkable efficacy, next generation vaccines should deliver broad protection against a wide spectrum of coronaviruses as well as improved robustness against newly emerging SARS-CoV-2 variants that threaten immune escape. The overall goal of this program is to design a pan-coronavirus vaccine strategy by coupling key immunological information regarding the B cell and antibody response (Project 1) with the T cell response (Project 2) from SARS-CoV-2 infection and vaccination to advanced structural design and vaccine delivery strategies (Project 3). This synergistic program seeks to design a protective, durable vaccine able to induce immunity across a spectrum of human as well as zoonotic coronaviruses. To do so will require a better understanding of the immunodominant epitopes targeted by B cells and T cells as well as the extent of cross-reactivity these responses have against conserved epitopes across coronavirus species. For T cells, which is the focus of Project 2, durable pan-coronavirus immunity will likely require robust cross-reactive responses by multiple effector subsets, including T helper type 1 (TH1), T follicular helper (TFH), and cytotoxic T cells (CTL) generated in both circulating and respiratory mucosal tissue-resident compartments. The overall goal of this project is to apply the knowledge gained from our studies of SARS-CoV-2-specific T cells in convalescent COVID-19 patients and vaccinees as well as innovative new experimental designs in mouse models to inform the design of vaccine immunogens by Project 3 that will maximize cross-reactive, yet durable and functionally diverse T cell immunity that will protect against multiple coronaviruses. We hypothesize that the quality of T cell immunity to coronaviruses varies by epitope and that pan-coronavirus vaccine design should incorporate epitopes based collectively on immunodominance, functional diversity, and breadth of cross-reactivity. The studies in this project will identify the best epitopes for this purpose. Specifically, we propose: 1) To identify SARS-CoV-2 CD4+ T cell epitopes from studies of convalescent COVID-19 patients and vaccinees that exhibit the greatest extent of immunodominance, durability, and cross-reactivity; 2) Evaluate the efficacy of cross-reactive CD4+ T cell epitopes in novel vaccine immunogens to induce protective immune responses in animal models; and 3) Discover new MHC class I epitopes using innovative screening technologies and evaluate their ability to generate protective CD8+ T cell responses in mice.", "keywords": [ "2019-nCoV", "Alleles", "Animal Model", "Antibody Response", "Antigens", "B-Lymphocytes", "Binding", "Biological Assay", "C57BL/6 Mouse", "CD4 Positive T Lymphocytes", "CD8-Positive T-Lymphocytes", "COVID-19", "COVID-19 patient", "COVID-19 vaccine", "Cell Line", "Chiroptera", "Coronavirus", "Coupling", "Cytotoxic T-Lymphocytes", "Dangerousness", "Development", "Epidemic", "Epitopes", "Exhibits", "Experimental Designs", "Frequencies", "Generations", "Goals", "Human", "Immune", "Immune response", "Immunity", "Immunodominant Epitopes", "Immunologic Memory", "Immunologics", "Individual", "Infection", "Intramuscular", "K-18 conjugate", "Knowledge", "Libraries", "Link", "MHC Class I Genes", "MHC binding peptide", "Memory B-Lymphocyte", "Methods", "Middle East Respiratory Syndrome", "Middle East Respiratory Syndrome Coronavirus", "Mucous Membrane", "Mus", "Patients", "Peptide/MHC Complex", "Peptides", "Phenotype", "Proteins", "Research Personnel", "Respiratory Mucosa", "Route", "SARS coronavirus", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Severe Acute Respiratory Syndrome", "Somatic Mutation", "Structure", "Structure of germinal center of lymph node", "T cell response", "T memory cell", "T-Lymphocyte", "T-Lymphocyte Epitopes", "Technology", "Testing", "Transgenic Mice", "Vaccinated", "Vaccination", "Vaccine Design", "Vaccines", "base", "betacoronavirus vaccine", "cross reactivity", "design", "efficacy evaluation", "global health", "human coronavirus", "human subject", "improved", "innovation", "mouse model", "novel vaccines", "pandemic disease", "programs", "response", "screening", "universal coronavirus vaccine", "vaccine candidate", "vaccine delivery", "vaccine efficacy", "zoonotic coronavirus" ], "approved": true } }, { "type": "Grant", "id": "16156", "attributes": { "award_id": "5R01AI190528-02", "title": "FEND-TB", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44239, "first_name": "NICOLE JOY", "last_name": "ESPY", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-10", "end_date": "2030-08-31", "award_amount": 2578047, "principal_investigator": { "id": 8100, "first_name": "David", "last_name": "Alland", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 925, "ror": "", "name": "RBHS-NEW JERSEY MEDICAL SCHOOL", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 27206, "first_name": "Jerrold J.", "last_name": "Ellner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 44240, "first_name": "Susan E", "last_name": "Dorman", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1856, "ror": "", "name": "RUTGERS BIOMEDICAL AND HEALTH SCIENCES", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true }, "abstract": "Among the estimated 10 million people with tuberculosis (TB) in 2022, over 3 million were not diagnosed, underscoring the need for new tools and diagnostic strategies to improve TB case detection, including in difficult to-diagnose populations such as children and people with extrapulmonary or early/subclinical TB. An equally urgent need is for drug susceptibility tests (DST) that can rapidly identify TB drug resistance/susceptibility, including to new drugs, to cure each person with TB and to protect the efficacy of newer drugs for those who may benefit from them in the future. Partially fueled by innovative platforms developed to address the COVID-19 epidemic, the last decade has seen a surge of new TB diagnostic platforms and assays. These new tests, sometimes developed by small companies with limited resources and little or no experience working with Mycobacterium tuberculosis (MTB) and clinical TB, require rigorous and unbiased evaluations. Furthermore, many diagnostic developers do not sufficiently appreciate the challenges presented by sample processing, the (often) need for high test sensitivity, or the acceptable tradeoffs between sensitivity/specific versus assay costs, ease of use and relevant target populations or TB disease states. Thus, the unmet needs of TB diagnostic developers are specific to the type of manufacturer, diagnostic technology, assay format, and intended use. Our proposal brings together a consortium of experienced investigators and a global network of clinical research sites to support TB diagnostic evaluations through a fast-paced and flexible pipeline that includes tech scouting, development mentoring, and clinical testing of early-stage TB diagnostics. With the inclusion of an Analytic Laboratory Core that can assess and help optimize new technologies prior to and after clinical studies our program offers a unique opportunity to accelerate promising TB diagnostics through their optimal development pipeline. Consortium members have almost three decades of leadership experience in diagnostic tech scouting, research, development, clinical trialing, and implementation activities. Fielding a balance of established platforms, fast followers, and cutting- edge technologies, we will perform the following specific aims: 1) identify promising early-stage diagnostics for evaluation and develop for each a stepwise evaluation plan; 2) evaluate the diagnostic accuracy of novel rapid point of care/near care TB diagnostics and determine the impact of relevant patient characteristics on test accuracy; and 3) provide feedback to diagnostic developers, policymakers, and other stakeholders on performance and usability of novel diagnostic tests and potential strategies for use in TB endemic settings.", "keywords": [ "Acceleration", "Address", "Adult", "Affect", "Biological Assay", "Biological Markers", "COVID-19 pandemic", "Caring", "Cause of Death", "Characteristics", "Child", "Childhood", "Clinical", "Clinical Research", "Clinical Trials", "Clinical assessments", "Communicable Diseases", "Communities", "Country", "Detection", "Development", "Diagnosis", "Diagnostic", "Diagnostic tests", "Diagnostics Research", "Disease", "Drug resistance", "Drug resistance in tuberculosis", "Enrollment", "Ensure", "Equilibrium", "Evaluation", "Feedback", "Funding", "Future", "HIV/TB", "Health", "India", "International", "Laboratories", "Leadership", "Manufacturer", "Mentors", "Mentorship", "Moldova", "Mycobacterium tuberculosis", "Patient Care", "Patient Recruitments", "Patient-Focused Outcomes", "Patients", "Performance", "Persons", "Peru", "Pharmaceutical Preparations", "Policy Maker", "Population", "Predisposition", "Process", "Reporting", "Research", "Research Personnel", "Resources", "Sampling", "South Africa", "Specificity", "Specimen", "Sputum", "Symptoms", "Target Populations", "Technology", "Testing", "Time", "Tuberculosis", "Tuberculosis diagnosis", "Uganda", "United States National Institutes of Health", "Vietnam", "Work", "biobank", "clinical diagnostics", "clinical research site", "comorbidity", "cost", "design", "diagnostic accuracy", "diagnostic assay", "diagnostic platform", "diagnostic strategy", "diagnostic technologies", "drug testing", "experience", "flexibility", "improved", "innovation", "member", "new technology", "novel", "novel diagnostics", "novel therapeutics", "performance site", "point of care", "precision medicine", "programs", "prospective", "prototype", "rapid test", "research clinical testing", "response", "tool", "treatment response", "tuberculosis diagnostics", "tuberculosis treatment", "usability" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1442, "count": 14420 } } }